Vanguard Global Advisers
CTNM

Vanguard Global Advisers’s Contineum Therapeutics CTNM Stock Holding History

Vanguard Global Advisers’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Hold
10,265
– – ﹤0.01% 2566
2026
Q1 		$134K Buy
+10,265
New +$138K ﹤0.01% 2606

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Global Advisers's CTNM Position: Q2 2026 in Review

Vanguard Global Advisers held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 10,265 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #2566.

Vanguard Global Advisers first reported a position in CTNM in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Vanguard Global Advisers held 10,265 shares of Contineum Therapeutics worth $168K as of Q2 2026.
  • Vanguard Global Advisers left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2566 holding.
  • Vanguard Global Advisers first reported a position in Contineum Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.